JP6019101B2 - 2−アミノ−2−[2−(4−オクチルフェニル)エチル]プロパン−1,3−ジオールを含む製剤 - Google Patents
2−アミノ−2−[2−(4−オクチルフェニル)エチル]プロパン−1,3−ジオールを含む製剤 Download PDFInfo
- Publication number
- JP6019101B2 JP6019101B2 JP2014502817A JP2014502817A JP6019101B2 JP 6019101 B2 JP6019101 B2 JP 6019101B2 JP 2014502817 A JP2014502817 A JP 2014502817A JP 2014502817 A JP2014502817 A JP 2014502817A JP 6019101 B2 JP6019101 B2 JP 6019101B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- composition
- mannitol
- octylphenyl
- propane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Description
a)2−アミノ−2−[2−(4−オクチルフェニル)エチル]プロパン−1,3−ジオール、その医薬上許容される塩、およびそのリン酸塩誘導体から選択される化合物、
b)充填剤、
c)安定剤、および任意で
d)結合剤および/または滑沢剤
を含む固体医薬組成物を提供する。
本発明の1つの特定の実施形態では、その塩は、塩酸塩である。
(a)安定剤、例えば、シクロデキストリンとS1P受容体調節因子との混合および得られた混合物の任意による粉砕および/または造粒;
(b)充填剤、例えば、糖アルコール、例えば、マンニトールの混合、得られた混合物の任意による粉剤および/または造粒;
(c)(b)で得られた混合物の任意による粉砕および/または造粒;および
(d)(b)または(c)で得られた粉砕および/または造粒を行った混合物と滑沢剤との混合
を含む医薬組成物の製造方法に関する。
(a)安定剤、例えば、シクロデキストリンとS1P受容体調節因子の混合および得られた混合物の任意による粉砕および/または造粒;
(a1)本発明の結合剤(例えば、ヒドロキシプロピルセルロース)と糖アルコール、例えば、マンニトールとの混合および得られた混合物の任意による粉砕および/または造粒;
(b)ステップ(a)および(a1)で得られた混合物の混合;
(c)(b)で得られた混合物の任意による粉砕および/または造粒;および
(d)(b)または(c)で得られた粉砕および/または造粒を行った混合物と滑沢剤との混合
を含む方法によって製造できる。
a)器官または組織移植拒絶の治療および予防、例えば、心臓、肺、心肺同時、肝臓、腎臓、膵臓、皮膚または角膜移植のレシピエントの治療および骨髄移植後に発生する場合がある移植片対宿主病の予防、特に、急性または慢性同種移植片拒絶および異種移植片拒絶の治療または、膵島細胞などのインスリン産生細胞の移植;b)例えば、長期慢性疾患、例えば、多発性硬化症、関節炎(例えば、関節リウマチ)、炎症性腸疾患、肝炎などの自己免疫疾患または炎症状態の治療および予防
に有用である。
1.上記に定義した疾患または状態の治療または予防に使用するための上記に定義した組成物;
2.有効量の上記に定義した組成物の対象への投与を含む、免疫調節を必要とする対象を治療する方法;
3.上記に定義した組成物の対象への投与を含む、上記に定義した疾患または状態を治療または予防する方法;
4.上記に定義した疾患または状態の予防または治療のための薬剤を調製するための上記に定義した医薬組成物の使用
を提供する。
本発明は以下の態様を包含し得る。
[1] a)2−アミノ−2−[2−(4−オクチルフェニル)エチル]プロパン−1,3−ジオール、その医薬上許容される塩、およびそのリン酸塩誘導体から選択される第1の化合物、
b)充填剤、および
c)シクロデキストリンまたはその誘導体を含む安定剤
を含む、経口投与に好適な固体医薬組成物。
[2] 前記組成物の全重量を基準にして、1.5重量%または1重量%未満(例えば、0.25重量%以下)の前記第1の化合物を含む、請求項1に記載の組成物。
[3] 0.5mg以下の前記第1の化合物を含む、請求項1に記載の組成物。
[4] 前記充填剤がマンニトールなどの糖アルコールを含む、前記請求項のいずれかに記載の組成物。
[5] ヒドロキシプロピルセルロースを含む結合剤などの結合剤をさらに含む、前記請求項のいずれかに記載の組成物。
[6] ステアリン酸マグネシウムを含む滑沢剤などの滑沢剤をさらに含む、前記請求項のいずれかに記載の組成物。
[7] 前記安定剤がヒドロキシプロピル−β−シクロデキストリンを含む、前記請求項のいずれかに記載の組成物。
[8] 前記第1の化合物が2−アミノ−2−[2−(4−オクチルフェニル)エチル]プロパン−1,3−ジオールまたはその医薬上許容される塩である、前記請求項のいずれかに記載の組成物。
[9] 自己免疫疾患を治療するための、前記請求項のいずれかに記載の組成物。
[10] 請求項1〜8のいずれか一項に記載の医薬組成物と共に、2−アミノ−2−[2−(4−オクチルフェニル)エチル]プロパン−1,3−ジオール、その医薬上許容される塩、およびそのリン酸塩誘導体から選択される化合物の治療有効量を投与することを含む、その必要のある患者において自己免疫疾患を治療する方法。
Claims (9)
- 前記組成物の全重量を基準にして、1.5重量%または1重量%未満(例えば、0.25重量%以下)の前記第1の化合物を含む、請求項1に記載の組成物。
- 0.5mg以下の前記第1の化合物を含む、請求項1に記載の組成物。
- 前記充填剤がマンニトールなどの糖アルコールを含む、請求項1〜3のいずれか1項に記載の組成物。
- ヒドロキシプロピルセルロースを含む結合剤などの結合剤をさらに含む、請求項1〜4のいずれか1項に記載の組成物。
- ステアリン酸マグネシウムを含む滑沢剤などの滑沢剤をさらに含む、請求項1〜5のいずれか1項に記載の組成物。
- 前記安定剤がヒドロキシプロピル−β−シクロデキストリンを含む、請求項1〜6のいずれか1項に記載の組成物。
- 前記第1の化合物が2−アミノ−2−[2−(4−オクチルフェニル)エチル]プロパン−1,3−ジオールまたはその医薬上許容される塩である、請求項1〜7のいずれか1項に記載の組成物。
- 自己免疫疾患を治療するための、請求項1〜8のいずれか1項に記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161470747P | 2011-04-01 | 2011-04-01 | |
US61/470,747 | 2011-04-01 | ||
US201161545835P | 2011-10-11 | 2011-10-11 | |
US61/545,835 | 2011-10-11 | ||
PCT/US2012/031340 WO2012135561A1 (en) | 2011-04-01 | 2012-03-30 | Formulations comprising 2 -amino- 2- [2- (4 - octylphenyl) ethyl] propane -1, 3 - diol |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014509652A JP2014509652A (ja) | 2014-04-21 |
JP6019101B2 true JP6019101B2 (ja) | 2016-11-02 |
Family
ID=45953284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014502817A Active JP6019101B2 (ja) | 2011-04-01 | 2012-03-30 | 2−アミノ−2−[2−(4−オクチルフェニル)エチル]プロパン−1,3−ジオールを含む製剤 |
Country Status (35)
Country | Link |
---|---|
US (5) | US9592208B2 (ja) |
EP (2) | EP3143990B1 (ja) |
JP (1) | JP6019101B2 (ja) |
KR (1) | KR102027014B1 (ja) |
CN (1) | CN103476400B (ja) |
AR (1) | AR085749A1 (ja) |
AU (1) | AU2012236357B2 (ja) |
BR (1) | BR112013024430B1 (ja) |
CA (1) | CA2831600C (ja) |
CL (1) | CL2013002810A1 (ja) |
CO (1) | CO6771459A2 (ja) |
CY (2) | CY1118423T1 (ja) |
DK (2) | DK3143990T3 (ja) |
EA (2) | EA027721B1 (ja) |
EC (1) | ECSP13012912A (ja) |
ES (2) | ES2773482T3 (ja) |
GT (1) | GT201300227A (ja) |
HK (1) | HK1190309A1 (ja) |
HR (2) | HRP20170021T1 (ja) |
HU (1) | HUE031286T2 (ja) |
IL (1) | IL228250B (ja) |
JO (1) | JO3177B1 (ja) |
LT (2) | LT3143990T (ja) |
MA (1) | MA34981B1 (ja) |
MX (1) | MX342522B (ja) |
MY (2) | MY175633A (ja) |
PE (2) | PE20140162A1 (ja) |
PL (2) | PL2694037T3 (ja) |
PT (2) | PT2694037T (ja) |
RS (1) | RS59917B1 (ja) |
SG (1) | SG193256A1 (ja) |
SI (2) | SI3143990T1 (ja) |
TW (1) | TWI528958B (ja) |
WO (1) | WO2012135561A1 (ja) |
ZA (1) | ZA201306636B (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014141298A2 (en) * | 2013-03-11 | 2014-09-18 | Astron Research Limited | Stable pharmaceutical composition of fingolimod |
CN103222966A (zh) * | 2013-04-01 | 2013-07-31 | 北京万全德众医药生物技术有限公司 | 一种含有盐酸芬戈莫德的固体药物组合物及其制备方法 |
WO2015015254A1 (en) | 2013-07-29 | 2015-02-05 | Aizant Drug Research Solutions Pvt Ltd | Pharmaceutical compositions of fingolimod |
CN106794159A (zh) * | 2014-08-22 | 2017-05-31 | 广东东阳光药业有限公司 | 一种芬戈莫德固体组合物及其制备方法 |
WO2016042493A1 (en) | 2014-09-19 | 2016-03-24 | Aizant Drug Research Pvt. Ltd | Pharmaceutical compositions of fingolimod |
EP3247341A4 (en) * | 2015-01-20 | 2018-12-19 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
EP3419607B1 (en) | 2017-03-29 | 2019-11-20 | Deva Holding Anonim Sirketi | Stable formulations of fingolimod |
US11135197B2 (en) | 2020-02-07 | 2021-10-05 | Argentum Pharmaceuticals Llc | Dosage regimen of an S1P receptor modulator |
WO2021158848A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor agonist |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
EP0627406B1 (en) | 1992-10-21 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
CZ285953B6 (cs) | 1995-12-28 | 1999-12-15 | Yoshitomi Pharmaceutical Industries, Ltd. | Vnější přípravek pro topické podání |
US6476004B1 (en) * | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
GB9624038D0 (en) | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
EP2030614A1 (en) | 1997-02-27 | 2009-03-04 | Novartis AG | Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin |
KR100551931B1 (ko) | 1997-04-04 | 2006-02-16 | 미츠비시 웰파마 가부시키가이샤 | 2-아미노프로판-1,3-디올 화합물, 이것의 의약으로서의 용도 및 합성 중간체 |
JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
JP4627356B2 (ja) | 1999-06-30 | 2011-02-09 | 松森 昭 | ウイルス性心筋炎の予防または治療薬剤 |
AU2001285331B2 (en) | 2000-08-31 | 2006-04-06 | Merck & Co., Inc. | Phosphate derivatives as immunoregulatory agents |
JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
DE122011100047I1 (de) * | 2003-04-08 | 2011-12-15 | Mitsubishi Tanabe Pharma Corp | Feste pharmazeutische darreichungsformen mit einemS1P rezeptoragonisten und einem zuckeralkohol. |
JP4861177B2 (ja) * | 2003-09-12 | 2012-01-25 | ニューロノバ エービー | 神経系の障害の処置 |
MX2007006706A (es) | 2004-12-06 | 2007-10-18 | Univ Virginia | Analogos de esfingosina 1-fosfato amida de arilo. |
GB0502358D0 (en) * | 2005-02-04 | 2005-03-16 | Novartis Ag | Organic compounds |
GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
TWI389683B (zh) | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
EP3103448B1 (en) | 2006-09-26 | 2019-07-03 | Novartis Ag | Pharmaceutical compositions comprising an s1p modulator |
EP2120575A4 (en) | 2006-12-21 | 2011-04-27 | Abbott Lab | AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS |
RU2010118457A (ru) | 2007-10-12 | 2011-11-20 | Новартис АГ (CH) | Композиции, содержащие модуляторы рецептора сфингозин-1-фосфата (sip) |
EP2358660A2 (en) | 2008-11-11 | 2011-08-24 | Novartis AG | Salts of fingolimod |
AR074826A1 (es) | 2008-12-22 | 2011-02-16 | Novartis Ag | Regimen de dosificacion para un agonista de los receptores de s1p |
-
2012
- 2012-03-29 JO JOP/2012/0074A patent/JO3177B1/ar active
- 2012-03-29 AR ARP120101074A patent/AR085749A1/es not_active Application Discontinuation
- 2012-03-30 MY MYPI2017000050A patent/MY175633A/en unknown
- 2012-03-30 MA MA36277A patent/MA34981B1/fr unknown
- 2012-03-30 DK DK16176665.4T patent/DK3143990T3/da active
- 2012-03-30 AU AU2012236357A patent/AU2012236357B2/en active Active
- 2012-03-30 PT PT127141638T patent/PT2694037T/pt unknown
- 2012-03-30 BR BR112013024430-5A patent/BR112013024430B1/pt active IP Right Grant
- 2012-03-30 PE PE2013002121A patent/PE20140162A1/es active IP Right Grant
- 2012-03-30 SI SI201231732T patent/SI3143990T1/sl unknown
- 2012-03-30 EA EA201391442A patent/EA027721B1/ru not_active IP Right Cessation
- 2012-03-30 RS RS20200141A patent/RS59917B1/sr unknown
- 2012-03-30 EA EA201790436A patent/EA035686B1/ru not_active IP Right Cessation
- 2012-03-30 MY MYPI2013003216A patent/MY163746A/en unknown
- 2012-03-30 SG SG2013065867A patent/SG193256A1/en unknown
- 2012-03-30 SI SI201230821A patent/SI2694037T1/sl unknown
- 2012-03-30 CA CA2831600A patent/CA2831600C/en active Active
- 2012-03-30 DK DK12714163.8T patent/DK2694037T3/en active
- 2012-03-30 LT LTEP16176665.4T patent/LT3143990T/lt unknown
- 2012-03-30 PL PL12714163T patent/PL2694037T3/pl unknown
- 2012-03-30 JP JP2014502817A patent/JP6019101B2/ja active Active
- 2012-03-30 MX MX2013011415A patent/MX342522B/es active IP Right Grant
- 2012-03-30 WO PCT/US2012/031340 patent/WO2012135561A1/en active Application Filing
- 2012-03-30 ES ES16176665T patent/ES2773482T3/es active Active
- 2012-03-30 EP EP16176665.4A patent/EP3143990B1/en active Active
- 2012-03-30 HU HUE12714163A patent/HUE031286T2/hu unknown
- 2012-03-30 PE PE2017000900A patent/PE20170913A1/es not_active Application Discontinuation
- 2012-03-30 US US14/009,241 patent/US9592208B2/en active Active
- 2012-03-30 TW TW101111547A patent/TWI528958B/zh active
- 2012-03-30 PL PL16176665T patent/PL3143990T3/pl unknown
- 2012-03-30 EP EP12714163.8A patent/EP2694037B1/en active Active
- 2012-03-30 KR KR1020137025398A patent/KR102027014B1/ko active IP Right Grant
- 2012-03-30 PT PT161766654T patent/PT3143990T/pt unknown
- 2012-03-30 ES ES12714163.8T patent/ES2610966T3/es active Active
- 2012-03-30 CN CN201280017346.1A patent/CN103476400B/zh active Active
- 2012-03-30 LT LTEP12714163.8T patent/LT2694037T/lt unknown
-
2013
- 2013-09-02 IL IL228250A patent/IL228250B/en active IP Right Grant
- 2013-09-04 ZA ZA2013/06636A patent/ZA201306636B/en unknown
- 2013-09-27 CO CO13230722A patent/CO6771459A2/es unknown
- 2013-09-27 GT GT201300227A patent/GT201300227A/es unknown
- 2013-09-30 CL CL2013002810A patent/CL2013002810A1/es unknown
- 2013-10-01 EC ECSP13012912 patent/ECSP13012912A/es unknown
-
2014
- 2014-04-09 HK HK14103389.7A patent/HK1190309A1/zh unknown
-
2017
- 2017-01-09 HR HRP20170021TT patent/HRP20170021T1/hr unknown
- 2017-01-12 CY CY20171100045T patent/CY1118423T1/el unknown
- 2017-01-30 US US15/418,831 patent/US20170135967A1/en not_active Abandoned
-
2018
- 2018-03-09 US US15/916,371 patent/US20180193291A1/en not_active Abandoned
-
2019
- 2019-04-23 US US16/391,506 patent/US20190247335A1/en not_active Abandoned
-
2020
- 2020-02-14 HR HRP20200249TT patent/HRP20200249T1/hr unknown
- 2020-02-24 CY CY20201100169T patent/CY1122868T1/el unknown
- 2020-05-18 US US16/876,336 patent/US20200276137A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6019101B2 (ja) | 2−アミノ−2−[2−(4−オクチルフェニル)エチル]プロパン−1,3−ジオールを含む製剤 | |
EP3103448B1 (en) | Pharmaceutical compositions comprising an s1p modulator | |
JP4868695B2 (ja) | 崩壊性が良好な経口製剤 | |
JP6739470B2 (ja) | デフェラシロクスの経口製剤 | |
EP3424499B1 (en) | A pharmaceutical composition for neuropathic pain | |
US20180344648A1 (en) | Clobazam tablet formulation and process for its preparation | |
US8512746B2 (en) | Extended release pharmaceutical compositions of levetiracetam | |
NZ615023B2 (en) | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol | |
SK11072000A3 (sk) | Tiagabínové prostriedky s predĺženým uvoľňovaním so zníženými vedľajšími účinkami | |
TW201618784A (zh) | 用於減緩周邊血管疾病病患間歇性跛行症狀的屬喹啉酮衍生物之西洛他唑(cilostazol)的新穎調配物 | |
UA112857C2 (uk) | Препарат, що містить 2-аміно-2-[2-(4-октилфеніл)етил]пропан-1,3-діол |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160223 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160511 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160920 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161003 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6019101 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |